90357-06-5
90357-06-5
Chemical Structure
Bicalutamide
- CAS No.: 90357-06-5
- Formula:C18H14F4N2O4S
- Molecular Weight:430.37
IUPAC Name: N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide
InChIKey: LKJPYSCBVHEWIU-UHFFFAOYSA-N
SMILES: FC1=CC=C(S(=O)(CC(O)(C(NC2=CC=C(C#N)C(C(F)(F)F)=C2)=O)C)=O)C=C1
Biological Activity: Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bicalutamide | 99.92% | Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bicalutamide (Standard) | ≥98% | Bicalutamide (Standard) is the analytical standard of Bicalutamide. This product is intended for research and analytical applications. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Bicalutamide-d5 | (R)-Bicalutamide-d5 is deuterated labeled (R)-Bicalutamide (HY-108250). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bicalutamide-d4 | Bicalutamide-d4 is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Bicalutamide (Standard) | (R)-Bicalutamide (Standard) is the analytical standard of (R)-Bicalutamide (HY-108250). This product is intended for research and analytical applications. (R)-Bicalutamide is the (R)-enantiomer of Bicalutamide (HY-14249). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
S-23 | 99.63% | S-23 is an orally active selective androgen receptor modulator (SARM) with a Ki of 1.7 nM. S-23 induces androgen receptor (AR)-mediated transcriptional activation in CV-1 cells. S-23 increases prostate, seminal vesicle, and levator ani muscle weights in castrated rats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UT-155 | 99.55% | UT-155 is a selective and potent androgen receptor (AR) antagonist, with a Ki of 267 nM for UT-155 binding to AR-LBD. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-UT-155 | 98.09% | (R)-UT-155 (compound 11) is a selective androgen receptor degrader (SARD) ligand. Less active than the S-isomer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ostarine | 99.90% | Ostarine (MK-2866) is a selective androgen receptor modulator (SARMs) that regulates cardiomyocyte function, improves bone healing, regulates uterine function, and influences muscle tissue metabolism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ostarine-d4 | Ostarine-d4 is a deuterated labeled Ostarine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SK33 | 99.98% | SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UT-34 | 98.09% | UT-34 is a potent, selective, orally bioactive second-generation pan-androgen receptor (AR) antagonist and degrader, with IC50 values of 211.7 nM, 262.4 nM, and 215.7 nM for wild-type AR, F876L-AR, and W741L-AR, respectively. UT-34 binds to the ligand-binding domain (LBD) and functional 1 (AF-1) domain of AR and requires the ubiquitin-proteasome pathway for AR degradation. UT-34 has anti-prostate cancer effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)thio)-2-hydroxy-2-methylpropanamide (Standard) | ≥98% | N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)thio)-2-hydroxy-2-methylpropanamide (Standard) is the analytical standard of N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)thio)-2-hydroxy-2-methylpropanamide. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
